Twist Bioscience Corporation (NASDAQ:TWST) on Monday posted better-than-expected sales for the first quarter.
The company posted first-quarter loss of 50 cents per share, in line with the Wall Street expectations. Sales reached $103.70 million, up 17% year over year, beating the consensus of $102.72 million, and the management guidance of $100 million-$101 million.
“As we continue through the year and beyond, we remain focused on driving toward profitability with consistent revenue growth, gross margins above 50% and disciplined spending to invest in scalable, sustainable growth opportunities while serving more customers, launching more products, and expanding our addressable markets,” said Emily Leproust, CEO and co-founder of Twist Bioscience.
Twist Bioscience …